|
|
| Line 1: |
Line 1: |
| {{drugbox | | | {{Ceftazidime}} |
| |width=300
| | __NOTOC__ |
| |IUPAC_name = (6''R'',7''R'',''Z'')-7-(2-(2-aminothiazol-4-yl)-<br />2-(2-carboxypropan-2-yloxyimino)acetamido)-8-oxo-<br />3-(pyridinium-1-ylmethyl)-5-thia-1-aza-bicyclo[4.2.0]<br />oct-2-ene-2-carboxylate
| | {{CMG}} |
| |CAS_number = 72558-82-8
| |
| | ATC_prefix=J01
| |
| | ATC_suffix=DD02
| |
| | PubChem=91713
| |
| | DrugBank=APRD00857
| |
| |C = 22 |H = 22 |N = 6 |O = 7 |S = 2
| |
| |molecular_weight = 546.58 [[Gram|g]]/[[Mole (unit)|mol]]
| |
| |bioavailability = 91% ([[intramuscular injection|IM]])
| |
| |metabolism = negligible
| |
| |elimination_half-life = 1.6–2 hours
| |
| |excretion = 90–96% [[Kidney|renal]]
| |
| |pregnancy_AU = B1
| |
| |pregnancy_US = B
| |
| |legal_AU = S4
| |
| |routes_of_administration = [[Intravenous therapy|Intravenous]], intramuscular
| |
| }}
| |
| {{SI}}
| |
| | |
| | |
| ==Overview==
| |
| '''Ceftazidime''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[kɛfˈtæzədim, sɛf-]}}) is a third-generation [[cephalosporin]] [[antibiotic]]. Like other third-generation cephalosporins, it has broad spectrum activity against [[Gram-positive]] and [[Gram-negative]] [[bacteria]]. Unlike most third-generation agents, it is active against ''[[Pseudomonas aeruginosa]]'', however it has weaker activity against Gram-positive microorganisms and is not used for such infections. '''Ceftazidime pentahydrate''' is marketed under various trade names including '''Fortum''' ([[GlaxoSmithKline|GSK]]).
| |
| | |
| ==Clinical use==
| |
| {{main|Cephalosporin}}
| |
| | |
| Ceftazidime is usually reserved for the treatment of infections caused by ''Pseudomonas aeruginosa''. It is also used in the [[empirical]] therapy of [[febrile]] [[neutropenia]], in combination with other antibiotics. The usual dose is 1–2 g [[intravenous|IV]]/[[intramuscular|IM]] every 8–12 hours(2 - 3times), though this can vary by the indication, infection severity, and/or renal function of the recipient.
| |
| | |
| ==Chemistry==
| |
| In addition to the ''syn''-configuration of the imino [[side chain]], compared to other third-generation cephalosporins, the more complex moiety (containing two [[methyl]] and a [[carboxylic acid]] group) confers extra stability to [[beta-lactamase|β-lactamase]] enzymes produced by many [[Gram-negative]] bacteria. The extra stability to β-lactamases increases the activity of ceftazidime against otherwise resistant Gram-negative organisms including ''Pseudomonas aeruginosa''. The charged [[pyridine|pyridinum]] moiety increases water-solubility.
| |
| | |
| ==See also==
| |
| *[[Cephalosporin]]
| |
| | |
| {{CephalosporinAntiBiotics}}
| |
| | |
| [[Category:Cephalosporin antibiotics]]
| |
| | |
| [[fr:Ceftazidime]]
| |
| [[pl:Ceftazydym]]
| |
| [[pt:Ceftazidima]]
| |
| [[th:เซฟตาซิดิม]]
| |
| [[zh:頭孢他啶]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WS}} | |